Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity fo...
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 64
- Registration Number
- NCT05142254
- Locations
- 🇳🇬
Murtala Mohammed Specialist Hospital, Kano, Nigeria
🇳🇬Aminu Kano Teaching Hospital, Kano, Nigeria
Endocan Level in Patients With Erectile Dysfunction and Relationship With Tadalafil Treatment
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Ankara Training and Research Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05109377
- Locations
- 🇹🇷
Veysel Bayburtluoğlu, Ankara, Turkey
Efficacy and Safety of Toronto Association in the Treatment of Erectile Dysfunction and Premature Ejaculation
- Conditions
- Interventions
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- EMS
- Target Recruit Count
- 232
- Registration Number
- NCT05052879
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2024-04-09
- Target Recruit Count
- 17
- Registration Number
- NCT05014776
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Dongkook Pharmaceutical Co., Ltd.
- Target Recruit Count
- 667
- Registration Number
- NCT04947631
- Locations
- 🇰🇷
Ewha Womans University mokdong Hospital, Seoul, Korea, Republic of
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT04757662
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Vigonvita Life Sciences
- Target Recruit Count
- 60
- Registration Number
- NCT04483115
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Fuwai Hospital CAMS&PUMC, Beijing, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Yan-Ping Huang
- Target Recruit Count
- 150
- Registration Number
- NCT04361305
A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 62
- Registration Number
- NCT04235270
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- WindMIL Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT04069936
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.